Theravance Biopharma (NASDAQ:TBPH) Sets New 12-Month High - Here's Why

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) shares reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $11.88 and last traded at $11.65, with a volume of 85478 shares. The stock had previously closed at $11.65.

Analyst Ratings Changes

TBPH has been the subject of a number of research analyst reports. BTIG Research increased their target price on shares of Theravance Biopharma from $24.00 to $25.00 and gave the stock a "buy" rating in a research report on Friday, June 27th. Wall Street Zen downgraded Theravance Biopharma from a "buy" rating to a "hold" rating in a report on Saturday, July 12th. Finally, Jones Trading raised shares of Theravance Biopharma to a "strong-buy" rating and set a $24.00 price objective for the company in a research report on Tuesday, June 17th. Four research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Theravance Biopharma has an average rating of "Moderate Buy" and an average target price of $16.60.

Theravance Biopharma Price Performance

The company has a fifty day moving average price of $10.39 and a 200 day moving average price of $9.64. The company has a market capitalization of $581 million, a P/E ratio of -9.85 and a beta of -0.02.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.16). The company had revenue of $15.39 million for the quarter, compared to the consensus estimate of $28.08 million. Theravance Biopharma had a negative return on equity of 32.37% and a negative net margin of 89.38%. On average, equities research analysts predict that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Theravance Biopharma news, SVP Rhonda Farnum sold 10,000 shares of the company's stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $11.39, for a total value of $113,900.00. Following the completion of the transaction, the senior vice president owned 326,918 shares in the company, valued at approximately $3,723,596.02. This represents a 2.97% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last 90 days, insiders have sold 48,000 shares of company stock valued at $527,800. Company insiders own 6.90% of the company's stock.

Hedge Funds Weigh In On Theravance Biopharma

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. raised its stake in shares of Theravance Biopharma by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 293,936 shares of the biopharmaceutical company's stock valued at $2,766,000 after purchasing an additional 2,060 shares in the last quarter. Teacher Retirement System of Texas bought a new stake in shares of Theravance Biopharma during the 4th quarter worth about $103,000. Magnetar Financial LLC lifted its stake in shares of Theravance Biopharma by 125.8% in the 4th quarter. Magnetar Financial LLC now owns 27,511 shares of the biopharmaceutical company's stock worth $259,000 after acquiring an additional 15,328 shares during the period. American Century Companies Inc. lifted its stake in shares of Theravance Biopharma by 11.9% in the 4th quarter. American Century Companies Inc. now owns 77,931 shares of the biopharmaceutical company's stock worth $733,000 after acquiring an additional 8,289 shares during the period. Finally, KLP Kapitalforvaltning AS bought a new position in shares of Theravance Biopharma in the fourth quarter valued at approximately $69,000. 99.10% of the stock is currently owned by institutional investors and hedge funds.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.